CADL Candel Therapeutics Stock Analysis: Thursday Predicted Opening Price & 5 Catalysts - Will It Su
1 extracted signal · 1 resolved · 0 still active
StockInvest.usIndependent analyst profile- Source published
- 02 Jul 2026, 13:21 UTC
- Recorded by Tahlil Plus
- 02 Jul 2026, 13:45 UTC
AI-generated source summary
Candel Therapeutics (CADL) is exhibiting a strong upward trend, with its 50-day moving average at $167.08 and 200-day moving average at $152.36, both indicating bullishness. The stock's current price of $9.88 is above these averages, supported by higher-than-average volume of 58.18 million shares, signaling increased investor interest. The company's price-to-earnings ratio stands at $5.89 with a P/E of 30.09, suggesting consistent growth and a potentially fair valuation. Technical analysis forecasts a potential increase of 75.78% to 86.96% over the next three months, with projected returns ranging from $17.44 to $18.48. The 12-month outlook suggests a potential increase of 26.33% to 33.69%, with price targets between $12.47 and $13.11. This stock is identified as a buy candidate with a high risk profile due to significant daily price movements and a sell signal from a recent pivot top, with a potential further decline indicated if the price falls below $9.74 or $8.65.
AI-generated summary based on the source content.
Signal outcomes at a glance
Evaluation CompleteSignals in this source
Evidence and evaluation progress
- Original source published
The analyst published the original source item.
- Source recorded by Tahlil Plus
The public source was preserved as the evidence record for this case.
- Market predictions extracted
1 eligible signal linked to this case.
- Source processing completed
Source analysis and structured extraction completed.
- Outcome tracking started
Tahlil Plus began monitoring the extracted predictions.
- First prediction resolved
The first evaluable outcome in this case reached a terminal result.
- Case evaluation completed
All evaluable predictions in this case reached terminal outcomes.
StockInvest.us
Platform-wide history, separate from this source evaluation.
Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.